Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in latent autoimmune diabetes in adults
ACTRN12626000382370Phase 2Not yet recruiting
- Sponsor
- MTF Biologics
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exenatide in latent autoimmune diabetes in adults (LADA), sponsored by MTF Biologics. Primary endpoint: Effect on C-peptide. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
exenatide
03
Conditions
latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on ACTRN12626000382370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000382370.